A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.